Lec 17- Vasodilators Flashcards

1
Q

Haemodynamic rationale and effect

A
  • Preload- vasodilation and reduction of intracardiac volume
  • After load- reduction in systemic vascular resistance
  • Coronary perfusion- Decreases myocardial schema , increase coronary blood flow to reduce O2 demand
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Preload revision

A
  • This is the volume of blood in the ventricle before contraction
  • This is based on venous pressure (venous return)
  • If increase right atrial pressure then get increased ventricle filling
  • Increased filling results in increased output
  • This is an increase in myocardial work and O2 requirements
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

After-load

A
  • Afterload is the peripheral BP that ventricular contraction must overcome
  • Ventricular contraction and cardiac output will compensate for increased after load
  • This is an increase in myocardial work and O2 requirement
  • Long term increase in arterial pressure results in ventricular hypertrophy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Coronary blood supply

A

-Angina- blockage via atherosclerosis, if we increase the diameter of the vessels allows blood to pass

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Coronary perfusion ‘The perfusion window’

A
  • Blood flow to the heart muscle only occurs during diastole
  • Increase HR means there is less time between beats therefore less time for blood to feed the heart so perfusion is decreases
  • An increase in ventricular end diastolic pressure will mean less blood flow to the heart
  • Reduced diastolic arterial pressure means less blood will flow to the heart
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clincal use of vasodilators

A
-Reduce cardiac preload 
\+Cardiac failure (CHF) 
\+Angina 
-Reduce cardiac after load- HTN 
-Local reductions in vascular resistance 
\+Prinzmetal's (variant) angina 
\+Peripheral vascular disease 
\+Raynauds disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pre-load reduction

A
  • Relaxation of veins will decrease cardiac filling pressure (pre-load)
  • Therefore use vasodilators with predominant venous action
  • Useful in CHF and in angina- sudden reduction in preload and so cardiac work
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Afterload reduction

A
  • Relaxation of arterioles will decreased resistance and reduce BP (HTN). Afterload reduction also useful in Angina and HF
  • Use vasodilators with predominant arterial action
  • The sum forces opposing ventricular emptying. Hypertrophy is a physiological mechanism due to increased afterload
  • Useful in cardiac failure to reduce cardiac work
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Coronary flow

A

-Relacation of arteries will increase flow to an Organ if arteries are narrowed (angina) and decrease afterload by increasing compliance (Useful in HF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Vasodilator drugs

A

Heterogenous Group: 2 major types
1) Directing acting: On vascular smooth muscle (VSM)- affect all constrictor agents
A- Drugs acting at ion channels
B-Drugs acting on NO systems
2) Indirectly acting or anti-vasoconstriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

A-Drugs acting on ion channels

A

1) Ca2+ channel blockers- inhibit voltage gated Ca2+ channels
2) K+ channel openers: Activates ATP dependant K+ channels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Muscle cell: cardiac or vascular

A

-Depolarisation, Ca2+ entry = contraction

-

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cardiac APs in general

A
  • Rapid depolarisation
  • Partial repolarisation (calcium shoulder, gives prolonged contraction)
  • Plateau
  • Depolarisation
  • Pacemaker potential
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Voltage gated calcium channels

A
  • Present in all excitable cells- muscles and nerves
  • Activated by cell depolarisation e.g. during cardiac AP
  • Different subtypes: L; N; P/Q; T
  • Different subtypes have different tissue distributions and functions
  • It is L-type channels that mediate voltage dependant Ca2+ entry into the muscle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

L-Type channel structure

A
  • The a1C subunit of the L-type Ca2+ channel is the pore-forming unit
  • Central function unit with similar structure to Na+ channels
  • 4 homologous domains each with 6-a helices membrane spanning segments (S1-6)
  • S4 contains +VE charged residues (voltage sensors)
  • a1 subunit structure defines subtype and is the target subunit for antagonists and agonists
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

L-Type blockers act selectively on cardiovascular tissues- important for therapeutic use

A

-Neurons rely on N and P-type channels
-Skeletal muscle relies primary on [Ca]i
-Cardiac muscle requires Ca2+ influx through L-type Ca2+ channels
+Contraction (e.g. ventricular myocytes)
+Upstroke of AP (pacemaker)
-Vascular smooth muscle requires Ca2+ influx through L-type Ca2+ channels for contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

CCBs- mechanism of action

A
  • Increase the time that Ca2+ channels are closed
  • Relaxation of there arterial smooth muscle but not much effect on venous smooth muscle
  • Reduce calcium entry into vascular smooth muscle and so produce vasodilation
  • Significant reduction in afterload BUT NOT preload
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

3 Modes of Ca2+ channel opening

A
Mode 0
-opening probability 0 
-Favoured by DHP antagonists 
-% of time spent in this mode <1%
Mode 1
-Opening probability low 
-% of time normally spent in this mode= 70% 
Mode 2
-Opening probability High 
-Favoured by DHP antagonists 
-% time open= 30% 

-Weather not channel opens affects the binding of the drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

3 classes of calcium channel blocker

A
  • Verapamil (phenylalkyamines)
  • Diltiazem (benzodiazepine)
  • Nifedipine (1,4-dihydropyridines)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

The different drugs have different channel binding region properties

A

-Use-dependant binding (Target AP conducting cardiac cells)
+Verapamil binds to area of the channel that is only exposed once the channel is open
-Voltage-dependant binding (target smooth muscle)
+Amlodopine needs the channel to be inactive inorder to bind, because of the voltage of the Ca2+ channels (-30mV) the channels are normally closed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Phenylalkyamines (verapamil)

A
  • Preferentially block channel;s in mode 1,2 so need opening
  • Preferential effect on cardiac cells
  • Use dependant, frequency dependant
  • Affect working cells, reduce contraction, sinus rate and AV conduction
  • Reduce myocardial contractility
  • Reduce HR
  • NB lots of interactions with other drugs
22
Q

Dihydropyridines (Amlodopine

A

-Preferentially block channels in mode 0, dependant on cells holding potential
-Voltage dependant- selective for vascular smooth muscle cells (due to their membrane potentials) compared with cardiac cells
-Reduce afterload and so myocardial work
-Little or no direct chronotropic or inotropic actions (But indirect effects due to vasodilations)
NB- can worsen HF, dosing dependant on release profile

23
Q

Hemodynamic effects of CCBs- Verapamil

A
  • Peripheral vasodilation: +
  • Coronary vasodilation: ++
  • preload: 0
  • Afterload: - -
  • Contractility: - -
  • HR: 0
  • AV conduction: - -
24
Q

Haemodynamic effects of CCBs- diltiazem

A
  • peripheral vasodilation: +
  • Coronary vasodilation: +++
  • preload: 0
  • Afterload: - -
  • Contractility: 0
  • HR: -
  • AV conduction: -
25
Q

Hemodynamic effects of CCB’s- amlodopine

A
  • peripheral vasodilation: ++
  • Coronary vasodilation: +++
  • preload: 0
  • Afterload: - - -
  • Contractility:
  • HR: 0 may increase barrow receptors
  • AV conduction: 0
26
Q

Use of Ca2+ channel blockers

A
  • HTN
  • Angina
  • Treatment of supra ventricular arrhythmias (verapamil only)
  • AF (diltiazem only)
27
Q

K+ channel openers

A
  • In excitable cells there are many K+ cells- important for setting and maintaining membrane potentials
  • Opening of K channels cause hyper polarisation- this occurs when you have low [ATP]
28
Q

Pharmacology on vascular smooth muscle

A
  • Highly selective for arterial smooth muscle due to the distribution of ATP sensitive channels. Virtually no effect on venous smooth muscle
  • Increase venous return due to increased flow in vascular beds. So increase in CO
  • Reduce insulin release from pancreas
  • Selectivity of action possible due to differential regulatory subunit expression
29
Q

The K+ channel openers and uses

A

-Nicorandidil (N-(2-hydroxyethyl) nicotinamide nitrate
+Duality of action: nitro vasodilator and K channel opener
+Angina- Coronary artery dilation and reduce afterload
-Minoxidil
+HTN- arterial vasodilation
+Shampoo- for hair growth
-Diazoxide- chemically one of the thiazide type diuretics
+Chronic intractable hypoglycemia (i.e. reduce insulin release)

30
Q

K+ channel opener side effects

A
  • Edema- water and salt retention as result of baroreceptor reflex, can also give loop diuretics to help
  • Hyperglycemia- due to effect on islet of Langerhans cells in pancreas, inhibiting insulin release
  • Cutaneous vasodilation: flushing; dizziness; headache
31
Q

K+ channel opener side effects

A
  • Edema- water and salt retention as result of baroreceptor reflex, can also give loop diuretics to help
  • Hyperglycemia- due to effect on islet of Langerhans cells in pancreas, inhibiting insulin release
  • Cutaneous vasodilation: flushing; dizziness; headache
32
Q

Directly acting vasodilators

B drugs acting on NO systems

A
  • Agents that increase cyclic nucleotides: in VSM both cAMP and cGMP are associated with relaxation. Many agents act via production of nitric oxide (NO) (Nitric oxide donors, nitro vasodilators)
  • Some agents inhibit breakdown (Phosphodiesterase)
33
Q

Physiological production of nitric oxide

A
  • Vascular smooth muscle cells are lined by endothelial cells and these mediated vasodilation
  • Blood vessels with added ACh it dilates, if this is damaged then this doesn’t occur
  • Blood flow causes shear stress on endothelial cells this causes an increase in Ca2+ in endothelial cells (NB- ACh and bradykinin also do this)
  • Ca2+ increase activates nitric oxide synthase –> NO
  • NO then diffuses into the muscle cell therefore this is a local action
  • NO activates guanylate cyclase which increases cGMP
  • cGMP associates with contractile proteins so inhibiting it causing relaxation
  • Phosphodiesterase breaksdown cGMP so inhibiting vasodilation
34
Q

Nitrates- Mode of action

A
  • When nitrates are in the blood they produce NO
  • Because NO is cell permeable it can cross lipid membrane through the endothelial cell into the smooth muscle cell
  • We bypass the physiological NO production
  • Short lived radical, activate soluble guanylate cyclase ….
35
Q

Nitro-vasodilators- actions

A
  • Vasodilator- preferential on venous muscle
  • At low rises fall in venous return (Preload) and in left ventricular stress
  • Higher doses fall in MAP (Afterload)
  • Potent coronary vasodilators. Modest effects in ischaemic heart disease
  • Improved sub-endocardial flow and collateral flow in partial coronary occlusion
  • No affect upon contractile state
  • Main effect is upon pre-load
36
Q

Nitrates in coronary artery disease

A
  • Atheromas usually block vessels so the resulting tissues then get reduced blood flow
  • By giving nitrate you cause dilation which will act to increase blood flow through the collateral arteries which is another path to the ischemic area increasing blood flow
37
Q

Nitrates Hemodynamic effects

A

1) Venous vasodilation
+Decreased pre-load causes
+Decrease pulmonary congestion
+Ventricular size reduction
+Decrease ventricular wall stress
+Decreased MVO2 (myocardial o2 consumption)
2)Coronary vasodilation causes increased myocardial perfusion
3)Arterial vasodilation causes decreased afterload
+Decreased CO
+Decreased BP

38
Q

Clinical use of nitrates

A
  • 1st agent was amyl nitrite
  • Primary use in angina
  • Sublingual glyceryl trinitrate peak plasma level in 1-2 min
  • Isosorbide mononitrate and denigrate (orally active, long lasting) for prophylaxis
  • Subject to tolerance due to exhaustion of enzymes (Guanylate cyclase) conversion to free NO
  • Main therapeutic approach is to allow nitrate free period 8-12 hours per day
  • Can cause hypotension, flushing and headaches
39
Q

Sodium nitroprusside

A

-Acts equally on venous and arterial smooth muscle
-Metabolised in vivo to release NO
-Active only by IV infusion- very rapid onset and short duration
-Highly effective for short term use in specialist units
NB DANGER: cyanide metabolite (can kill)

40
Q

Phosphodiesterase inhibition

A
  • This is exploitation of physiological system
  • By inhibiting phosphodiesterase this means that cGMP is not being broken down
  • This vastly increases [cGMP] so increase in dilation
41
Q

Phosphodiesterase inhibitors

A
  • Many subtypes of phosphodiesterase which are differentially expressed, so there is a large potential for targeted action/prescription
  • Phosphodiesterase inhibition leads to cGMP build up in VSM cell
  • Cilostazol type II PDE inhibitor used for PVD (peripheral, vascular disease)
  • Enoximone exerts most effect on the myocardi ; it has positive inotropic properties and vasodilator activity used in HF with reduced CO and filling pressures (Special inpatient units)
  • Sildenafil- selective for type V PDE, found in corpus cavernosum
42
Q

Hydralazine

A

-Directly acting vasodilator of unknown mode of action. seems to inhibit IP3, activation of Ca2+ release from sarcoplasmic reticulum
-Highly arterial selective. More effective on renal, coronary and cerebral circulation
-Used short term treatment of acute HTN in pregnancy and Intensive care settings
-HTN in renal failure
-HF in combination with nitrates
-But longer term high dose can lead to immune disorders
+Test for ANF and for proteinuria every 6 months
+Check acetylator status before increase dose above 100mg dd

43
Q

2) Indirectly acting vasodilator drugs

A

-Agents act to block vasoconstrictor effects of signalling systems in the cardiovascular system

44
Q

Vascular smooth muscle

A
  • GPCR’s are expressed by muscle cells
  • NA (alpha 1- GPCR)
  • Angiotensin II (AT-1 receptors)
  • NA release binds to GCPR and causes increase in IP3 leading to Ca2+ increase causing contraction
45
Q

Alpha-1 antagonist

A

-Prazosin (doxasoin) Causes vasodilation and fall in arterial BP
-Sympathetic system controls bP on minute to minute basis therefore, antagonising alpha adrenoceptors is especially useful and therefore widely used in the treatment of HTN from step 3
-Also used for Benign prostatic hyperplasia (BPH)
NB: can cause dizziness and postural hypotension; can cause increase in urinary frequency

46
Q

Angiotensin II

A
  • Produced in response to reductions in BP
  • Angiotensin II si an extremely potent vasoconstrictor via activation of AT-1 receptor
  • Angiotensin II also increases NA release from sympathetic nerves
47
Q

RAAS

A
  • Sympathetic B1 stimulation or a drop in BP
  • Kidney –> renin
  • Angiotensinogen in plasma gets converted by renin into angiotensin I
  • ACE( bradykinin breaks this down) converts Angiotensin I –> angiotensin II
  • Angiotensin II causes fluid and salt retention; vasoconstriction and increase in TPR and afterload
48
Q

Therapeutic targets

A
  • ACEI- preferentially vasodilators kidneys, heart and brain
  • AT1- receptor antagonists
  • Renin inhibits
49
Q

Vasodilator classification

A

Venous: Nitrates
Mixed: a-adrenergic blockers; ACEI; Angiotensin II inhibitor; K+ channel activators; nitroprusside
Arterial: Minoxidil; hydrazine

50
Q

Use of vasodilators

A

HTN
-Selective dilators of arterioles (reduce peripheral resistance_
+Amlodopine
+Hydralazine
+Minoxidil
+Nitroprusside (Emergencies only)
Angina
-Reduce cardiac workload and improve coronary perfusion
+Nitrates- selective for veins and large arteries
+CCB’s- selective for arterioles and cardio-depressant: Benzothiazepines
+Nicorandil
Heart Failure
-Reduce preload and afterload
+Nitrates (reduced pre-load)
+Hydralazine
+PDE inhibitor- enoximone (where reduced CO and filling pressure)
Atrial Fibrillation
-Diltiazem